NASDAQ:MGTA - Magenta Therapeutics Stock Price, Forecast & News

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Magenta Therapeutics Inc (NASDAQ:MGTA) released its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.54) by $0.00. View Magenta Therapeutics' Earnings History.

Magenta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Magenta Therapeutics.

5 brokerages have issued 1 year price objectives for Magenta Therapeutics' stock. Their forecasts range from $18.00 to $22.00. On average, they expect Magenta Therapeutics' share price to reach $20.00 in the next twelve months. This suggests a possible upside of 64.6% from the stock's current price. View Analyst Price Targets for Magenta Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Magenta Therapeutics.

News stories about MGTA stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Magenta Therapeutics earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Magenta Therapeutics.

Some companies that are related to Magenta Therapeutics include Prestige Consumer Healthcare (PBH), Karuna Therapeutics (KRTX), Principia Biopharma (PRNB), Cambrex (CBM), Forty Seven (FTSV), Eidos Therapeutics (EIDX), Xencor (XNCR), Pacira Biosciences (PCRX), Turning Point Therapeutics (TPTX), Heron Therapeutics (HRTX), IGM Biosciences (IGMS), Tricida (TCDA), Ironwood Pharmaceuticals (IRWD), Zymeworks (ZYME) and Ligand Pharmaceuticals (LGND).

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Aduro BioTech (ADRO), Cidara Therapeutics (CDTX), Crispr Therapeutics (CRSP), Melinta Therapeutics (MLNT), Nabriva Therapeutics (NBRV), Progenics Pharmaceuticals (PGNX) and T2 Biosystems (TTOO).

(MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Magenta Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Eventide Asset Management LLC (8.70%), Casdin Capital LLC (7.95%), State Street Corp (0.93%), Geode Capital Management LLC (0.66%), Platinum Investment Management Ltd. (0.53%) and Marshall Wace North America L.P. (0.33%). Company insiders that own Magenta Therapeutics stock include Bruce Booth, David Scadden, Jason Gardner, John C Davis Jr and Michael P Cooke. View Institutional Ownership Trends for Magenta Therapeutics.

MGTA stock was sold by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., Russell Investments Group Ltd., New York State Common Retirement Fund, Bank of America Corp DE and ProShare Advisors LLC. Company insiders that have sold Magenta Therapeutics company stock in the last year include Bruce Booth, Jason Gardner, John C Davis Jr and Michael P Cooke. View Insider Buying and Selling for Magenta Therapeutics.

MGTA stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Marshall Wace North America L.P., Casdin Capital LLC, California Public Employees Retirement System, State Street Corp, Geode Capital Management LLC, Bailard Inc. and OneAscent Financial Services LLC. Company insiders that have bought Magenta Therapeutics stock in the last two years include David Scadden and Jason Gardner. View Insider Buying and Selling for Magenta Therapeutics.

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MGTA stock can currently be purchased for approximately $12.15.

Magenta Therapeutics has a market capitalization of $473.73 million. The company earns $-57,510,000.00 in net income (profit) each year or ($3.13) on an earnings per share basis. Magenta Therapeutics employs 59 workers across the globe.View Additional Information About Magenta Therapeutics.

The official website for Magenta Therapeutics is http://www.magentatx.com/.

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]